Purpose: To evaluate the safety and efficacy of tacrolimus eye drops as adjunctive therapy in the treatment of severe corneal endothelial rejection after penetrating keratoplasty refractory to corticosteroids.
Methods: In this prospective interventional case series, 11 eyes of 11 patients assessed for severe corneal endothelial rejection, with an inadequate response to topical, local, and systemic corticosteroids, were treated with either 0.01% or 0.05% tacrolimus eye drops 4 times daily. Improvement in signs of rejection, visual function, and development of complications were monitored.
Results: The duration of steroid treatment before intervention was 8.1 ± 1.4 days (range = 7-11). Patients were subsequently administered topical tacrolimus 0.01% or 0.05% qid. The time to clinical improvement was 10.3 ± 3.4 days (range = 3-17). The time to rejection reversal was 27.8 ± 16.3 days (range = 7-52). After 3 months, 10 patients (90.8%) demonstrated clinical improvement, and complete restoration of graft clarity was achieved in 5 patients (45.4%). In responsive cases, steroid therapy was successfully tapered off after 60.2 ± 19.7 days (range = 36-93). The best spectacle-corrected visual acuity improved from 1.7 ± 0.9 to 0.8 ± 0.5 logMAR (P = 0.0016). Reported side effects included stinging on drop instillation and punctate epithelial keratopathy.
Conclusions: Tacrolimus eye drops may be able to play an adjunctive therapeutic role in patients with severe corneal endothelial rejection refractory to conventional steroid treatment. Controlled studies are needed to further investigate the role of tacrolimus in this setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ICO.0000000000001298 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recurrence rate of corneal squamous cell carcinoma in dogs undergoing superficial keratectomy surgery.
Open Vet J
November 2024
Animal Eye Care, Melbourne, Australia.
Background: Corneal squamous cell carcinoma (cSCC) is a rare neoplasm of dogs that can be treated with various modalities, principally by superficial keratectomy (SK) surgery. It is common to treat cSCC with multiple adjunctive therapies, but this may not always be practical for clinicians, clients, or patients.
Aim: This retrospective study describes the signalment of affected dogs, concurrent medical therapy, and success rate of surgical treatment of cSCC with SK surgery alone or in combination with adjunct therapy.
Efficacy of mycophenolate mofetil combined with topical 0.05% tacrolimus in high-risk keratoplasty: 1-year cohort study.
Int J Ophthalmol
December 2024
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou 510060, Guangdong Province, China.
Aim: To investigate the efficacy of systemic mycophenolate mofetil (MMF) as an adjunct in combination with topical tacrolimus (FK506) and corticosteroid eyedrops for preventing corneal graft rejection after high-risk keratoplasty (HRK).
Methods: In this cohort study, 55 consecutive patients (55 eyes) from an eye center who met the criteria of HRK were included. The definition for HRK includes large grafts of no less than 9 mm diameter, vascularized cornea of two or more quadrants, regrafting, or eccentric grafts.
Evaluating anterior corneal surface using Placido ring mires for irregular astigmatism in refractory corneal subepithelial infiltrates after adenoviral conjunctivitis.
BMC Ophthalmol
November 2024
Nagata Eye Clinic, 1147 Kitayamada Hohrai, Nara-City, 6310844, Nara, Japan.
Article Synopsis
- Corneal subepithelial infiltrates (SEIs) can lead to vision problems in patients with adenoviral keratoconjunctivitis (AKC), often causing irregular astigmatism that is overlooked.
- An 8-year-old girl with AKC experienced recurring vision issues despite treatment, revealing that her vision loss was due to an irregular corneal surface rather than corneal opacity.
- Treatment with 0.1% tacrolimus eye drops proved effective in addressing both the corneal opacity and the irregular surfaces, emphasizing the importance of using Placido ring topography for diagnosis and monitoring.
Multiple pathogen infections accompanied with ocular pathologies in a patient with high-titer Anti-IFN-γ autoantibodies: a case report.
BMC Infect Dis
November 2024
Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, No. 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, P.R. China.
Article Synopsis
- Patients with high levels of anti-IFN-γ autoantibodies (AIGAs) often suffer from infections caused by intracellular pathogens, as well as associated immune disorders.
- A 53-year-old woman with high titers of AIGAs was hospitalized due to a mass, leading to diagnoses of multiple infections including Talaromyces marneffei and Aspergillus flavus.
- Despite extensive treatment including antifungal and anti-NTM therapies, the patient experienced rapid recurrence of infections and developed ocular problems, which were managed with eye drops and lubricants.
Clinical and pathologic characteristics of inflamed juvenile conjunctival nevus and its treatment with immunosuppressant eye drops.
Jpn J Ophthalmol
November 2024
Department of Ophthalmology, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, 573-1191, Osaka, Japan.
Purpose: To clarify the clinical and pathologic findings of 7 patients with inflamed juvenile conjunctival nevus (IJCN) treated with tacrolimus.
Study Design: Retrospective study.
Subjects And Methods: The medical records of 7 male patients diagnosed with IJCN between February 2007 and October 2022 at the Kansai Medical University Hospital and Ideta Eye Hospital were retrospectively reviewed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!